#Japan #healthcare #Sagamihara #Lotte Holdings #Physiologas

Lotte Holdings' Strategic Investment in Healthcare Innovation

In a significant move to bolster its healthcare portfolio, Lotte Holdings Co., Ltd. has announced an investment in Physiologas Technologies, a Kanagawa-based healthcare startup spun off from Kitasato University. The investment was made through Lotte's Healthcare Bio Pharmaceuticals Venture Capital (HB-CVC) initiative, marking the first foray into the medical device sector by the company.

Based in Sagamihara City, Physiologas Technologies was founded in 2020, focusing on the development of next-generation blood dialysis machines designed for home use at the preclinical stage. With proprietary technologies, the company is innovating advanced potassium and uremic toxin adsorptive filters, in-line monitoring and control functions, and patient data analysis capabilities. These features promise to yield a compact, user-friendly dialysis machine that can improve the quality of life for chronic kidney disease (CKD) patients while cutting down on healthcare costs.

Traditionally, home dialysis has relied on extensive water infrastructures, requiring hundreds of liters for treatment and waste disposal. Physiologas' new technology aims to revolutionize this process, providing patients with an easier and more accessible treatment option. As a response to the growing global challenge of CKD, which affects over 800 million people worldwide, the development of such advanced healthcare technologies has become increasingly crucial.

Lotte Holdings will act as the lead investor in this Series A funding round, supporting Physiologas through the finalization of prototypes, the execution of preclinical trials, and preparing for regulatory discussions with Japan's Pharmaceuticals and Medical Devices Agency and the U.S. Food and Drug Administration. This strategic investment reflects Lotte's commitment to driving forward the advancement of cutting-edge technologies in the healthcare sector.

Dr. Joon Paek, Managing Partner of HB-CVC at Lotte, expressed optimism about Physiologas' potential: "Physiologas possesses an innovative yet straightforward technology that can fundamentally transform traditional blood dialysis treatments. By providing home treatment options, they can significantly enhance the quality of care and life for dialysis patients worldwide. We are dedicated to supporting them as they pave the way in the expanding field of home healthcare."

Lotte Holdings' Commitment to Health

Lotte Holdings' strategic direction aligns with its goal of expanding its business into the healthcare and bio-pharmaceutical sectors, seeking solutions to global health challenges. Lotte, a leader in various sectors such as confectionery, real estate, finance, and entertainment, is committed to innovation and integration of its diverse business lines to create positive societal impacts.

The investment in Physiologas Technologies not only strengthens Lotte's healthcare portfolio but also reflects its broader vision as a 'Lifetime Value Creator', emphasizing sustained value creation throughout individuals’ life cycles. As the company continues to explore innovative solutions in health and wellness, it aims to contribute to creating a healthier society.

Physiologas Technologies: Pioneering Home Dialysis

Physiologas Technologies is breaking new ground in medical devices designed for dialysis treatment. With features like advanced monitoring and data analytics, they pave the path for safer and more efficient home dialysis solutions. By eliminating the need for extensive water systems typically required in traditional home dialysis, the company's compact and easy-to-install solutions enhance the quality of life for CKD patients tremendously.

As Lotte Holdings and Physiologas join forces, the future of home healthcare looks promising, with an eye towards expanding access and improving outcomes for those in need. To learn more about Lotte Holdings, visit their website and for details about Physiologas Technologies, see their site.